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Abstract
Background: Properly performed systematic reviews and meta-analyses are thought by many to
represent among the highest level of evidence addressing important clinical issues. Few would
disagree that meta-analyses based on individual patient data (IPD) offer several advantages and
represent the standard to which all other systematic reviews should be compared.
Methods: All cancer-related meta-analyses cited in Medline were classified as based on aggregate
or individual patient data. A review was then undertaken of all reports comparing the comparative
strengths and limitations of meta-analyses using either aggregate or individual patient data.
Results: The majority of published meta-analyses are based on summary or aggregate patient data
(APD). Reasons suggested for this include the considerable resources, years of study and often,
broad international cooperation required for IPD meta-analyses. Many of the most important
features of systematic reviews including formal meta-analyses are addressed by both IPD and APD
meta-analyses. The need for defining an explicit and relevant clinical question, exhaustively
searching for the totality of evidence, meticulous and unbiased data transfer or extraction,
assessment of between study heterogeneity and the use of appropriate statistical methods for
estimating summary effect measures are essentially the same for the two approaches.
Conclusion: IPD offers advantages and, when feasible, should be considered the best opportunity
to summarize the results of multiple studies. However, the resources, time and cooperation
required for such studies will continue to limit their use in many important areas of clinical medicine
which can be meaningfully and cost-effectively approached by properly performed APD meta-
analyses. APD meta-analyses continue to be the mainstay of systematic reviews utilized by the US
Preventive Services Task Force, the Cochrane Collaboration and many professional societies to
support clinical practice guidelines.
Background
A meta-analysis strives to obtain data on all patients in all
relevant trials addressing an explicit and relevant clinical
question. Meta-analyses most often attempt to achieve
these goals by collecting aggregate patient data (APD)
from completed studies that have been published in the
medical literature, presented at professional meetings or
directly provided by individual investigators. Few would
argue that properly conducted meta-analyses based on
individual patient data (IPD) have several advantages and
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represent the standard against which other meta-analyses
should be considered. While the relative advantages and
disadvantages of meta-analyses based on either APD or
IPD have been debated in the medical literature, the
majority of published meta-analyses continue to be based
on APD. In addition, APD meta-analyses continue to be
the mainstay of systematic reviews conducted by the US
Preventive Services Task Force, the Cochrane Collabora-
tion and many professional societies. A systematic search
for IPD meta-analyses related to cancer in 2000 confirmed
38 of which 8 were unpublished [1]. A more recent search
of Medline by the authors identified 1,595 reported meta-
analyses related to cancer of which 76 (4.4%) were appar-
ently based on IPD. The annual proportion of published
cancer meta-analyses based on IPD has not changed sig-
nificantly over the last several years (Figure 1). A recent
review of IPD meta-analyses to evaluate diagnostic tests
found no published reports of IPD meta-analyses in diag-
nostic research [2]. That the majority of published system-
atic reviews are based on APD meta-analyses suggests that
they are not only more frequently completed but may also
be considered relevant and valid to editors, reviewers and
readers. Given the virtually infinite number of clinical
questions that might be addressed in systematic reviews,
it is important and timely to review the methodological
differences and the relative advantages and disadvantages
of these two types of meta-analysis.
Methods
Many of the reasons why meta-analyses are generally con-
sidered high-level evidence pertain to both IPD and APD.
In the case of both APD and IPD meta-analyses, a written
Bar graph representing the number of published meta-analyses related to cancer and cited in MEDLINE over the past fifteen  years Figure 1
Bar graph representing the number of published meta-analyses related to cancer and cited in MEDLINE over the past fifteen 
years. Shown are the total number of reported meta-analyses and the proportion of meta-analyses each year indicating an indi-
vidual patient data meta-analyses. Note that data for 2004 is incomplete.
63 68 92 68 79 67 75 86 96 108 167 121 140 167 127
0
20
40
60
80
100
120
140
160
180
200
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
P
u
b
l
i
s
h
e
d
M
e
t
a
-
A
n
a
l
y
s
e
s
2.9% 4.3%
6.3%
9.5%
9.4%
4.4%
3.5%
6.9%
6.0%
4.0%
1.1%
2.5%
5.2%
1.4% 0.0%
IPD Meta-analyses
APD Meta-analysesBMC Medical Research Methodology 2005, 5:14 http://www.biomedcentral.com/1471-2288/5/14
Page 3 of 7
(page number not for citation purposes)
study protocol should be generated pre-specifying the
search process, inclusion and exclusion criteria and the
hypotheses to be tested. Criteria for study inclusion and
exclusion should be defined in advance and uniformly
applied. In both situations, an exhaustive search for rele-
vant studies should be conducted. In addition, careful
data collection based on dual data extraction and entry
should be employed. Both the primary and secondary
outcomes of interest should be specified in advance of
data extraction or analyses. The results from individual
studies are then systematically analyzed first by assessing
for heterogeneity and, if appropriate, combining of results
providing summary estimates of the treatment effect. Sec-
ondary analyses then are often performed to explore the
reasons for any heterogeneity. Publication bias represents
an important limitation of any review and retrieval of data
from all relevant studies should be the goal in order to
avoid publication bias. Cochrane reviews attempt to iden-
tify all relevant studies, published and unpublished, and
this should be the goal of any systematic review based on
either IPD or APD. An acknowledged limitation of IPD is
the need to exclude studies for which data are not availa-
ble due to time, willingness or proprietary interest. There-
fore, before abandoning APD meta-analyses, it is
important to look more closely at the pros and cons of
each approach.
Results
The strengths and limitations of APD meta-analyses
The purpose of a meta-analysis is to systematically review
the results of previous research in order to derive valid
conclusions concerning totality of evidence on a subject.
Both IPD and APD meta-analyses attempt to avoid the
potential bias of narrative literature reviews, which are
selective in the studies included and subjective in the
weighting of the studies included. Each is considered use-
ful for summarizing the results of multiple individual
studies that are each too small to provide valid results.
Pooled analyses of APD is conceptually the same as meta-
analyses of separate studies based on IPD including esti-
mating study-specific treatment effects, assessing hetero-
geneity, estimating a summary effect size and evaluation
of heterogeneity.
Strengths and limitations of IPD meta-analyses
Several authors have discussed the strengths and potential
advantages of IPD meta-analyses [3,4]. Table 1 summa-
rizes many of the suggested advantages of IPD meta-anal-
yses. Authors have gone so far as to suggest that meta-
analyses based on APD provide little reliable information
and should be viewed as only exploratory [5]. Many of the
stated advantages of IPD meta-analyses are not inherent
to the analysis but rather represent epiphenomena that
often accompany the enormous resources, time and
energy devoted to IPD meta-analysis. As shown in Table 2,
many of the specific steps provide such systematic reviews
with their procedural superiority over narrative reviews
are shared by IPD and APD analyses. It is also clear that in
addition to considerable cost and years of effort, IPD
meta-analyses often require the extraordinary cooperation
of all original investigators, institutions, organizations,
companies and investigational review boards to avoid
publication bias that may challenge the validity of the
analysis since the missing studies are seldom missing
completely at random. Such studies also offer the strong
temptation to conduct unplanned subgroup analyses for
which the original studies were neither designed nor pow-
ered based on patient-specific data. It is essential to avoid
the temptation to combine all patients as if they came
from a single very large clinical trial. Most IPD meta-anal-
yses use essentially the same summary and statistical
measures employed for analysis of aggregate data. Clearly
IPD meta-analyses often obtain updated data and perform
checks on the original data when possible. However,
again, these strategies are not inherent to the IPD process
but reflect the additional resources and effort that is often
employed in such analyses. Additional issues to consider
in contrasting these different approaches are summarized
below:
a) Data access and checking
Gaining access to IPD in an era of increasing concern
about confidentiality and greater oversight is not a trivial
undertaking. In addition, access to IPD does not guaran-
tee that the data collection was properly conducted, that
the randomization process was appropriate or that the
same data items were actually collected. Rarely does an
IPD meta-analysis provide access to the source data such
as patients, medical records, laboratory results etc. Rather,
access is provided to data extracted at the point of care on
each patient and the true accuracy of the APD is often not
verified. It is argued that an advantage of IPD is the ability
to check the data reported in the published trial. While
data checking is sometimes considered, it is very costly
and time consuming process and rarely undertaken.
Table 1: Proposed advantages of individual patient data meta-
analyses
Ability to use common definitions, coding and cutpoints
Address questions not addressed in original publication
Assess adequacy of randomization
Permits data checking
Permits data updating
Permits checking of analyses
Allows adjustment for the same variables across studies
Permits ready use of time-to-event data for estimating survival
Ability to address long-term outcomes
Facilitates exploration of heterogeneity at the patient level and 
subgroup analyses of patient level dataBMC Medical Research Methodology 2005, 5:14 http://www.biomedcentral.com/1471-2288/5/14
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When checked data has been compared to unchecked
data, differences in estimated outcomes are rare [6]. Even
when all data are available rather than only summary
data, analyses are generally based on meta-analysis esti-
mators of treatment effect as in APD meta-analyses. Sev-
eral studies have demonstrated that when the pool of
studies is the same and similar measures are utilized, the
effect size estimates for appropriate procedures are very
similar for IPD and APD meta-analysis [7,8].
b) Updated data
Another possible advantage to IPD meta-analysis is the
ability to update data from a previous publication provid-
ing longer follow-up with a greater number of events.
Although updated data is more likely to become available
with the extended resources and collaboration of individ-
ual investigators, it must be noted that updating of previ-
ously published data is not inherent nor confined to IPD
meta-analysis. It has been pointed out, in fact, that
unpublished data and late-appearing data may be differ-
ent from early-appearing data [9]. Updated data available
after the completion of the main study may be affected by
crossover, missing information and unblinding. Using
data from a study of the effect of high-dose acyclovir on
the survival of patients with HIV, the authors found that
APD and IPD lead to the same effect estimates. They con-
clude that discrepant results probably arise either by pub-
lication bias or retrieval bias in the IPD analyses or the
inclusion of updated information that differentiates the
databases used by the two methods but is not inherent to
or exclusive of either.
c) Data accuracy and validity
Some authors have concluded that the results of IPD
meta-analyses are more accurate and unbiased than those
based on APD [11,12]. However, such reports often
equate literature-based meta-analyses and those based on
APD. Comparisons based on meta-analyses limited to
published reports may be inherently biased if the IPD
analysis includes the results of unpublished studies as was
done in the above reports. Unpublished studies are often
unpublished due to low observed treatment effect either
leading the investigators not to pursue publication or edi-
torial bias against negative study results. Stewart and
Palmar [11] compared the results with the unpublished
studies included and found a small but persistent differ-
ence between the effect estimates of the two approaches.
It is likely that much of the remaining difference related to
the ability of IPD investigators to obtain updated results
compared to literature-based analyses where no such
effort was made. It should be noted that there is no inher-
ent obstacle to including aggregate data from unpublished
results if they have been reported in abstract form, pre-
sented at major meetings or are willingly provided as sum-
mary measures by the investigators. Likewise, there is no
barrier other than needed resources, time and cost to
requesting updated summary measure from authors of
published studies. Therefore, the favorable findings often
reported for IPD meta-analyses may relate to the inclusion
of additional, unpublished studies with low treatment
effect and the addition of updated data from individual
investigators. There are many unresolved issues related to
the need for informed consent and HIPPA compliance for
Table 2: Comparison of IPD and APD Meta-Analyses
Steps in Meta-Analysis IPD APD
Explicit and Relevant Clinical Question √√
Exhaustive Search All published studies √√
All presented studies √√
All completed studies √ ±
Screening: inclusion/exclusion criteria √√
Data Acquisition (extraction/transfer) Aggregate data √√
Individual patient data √ -
Data Checking Source data ± -
Submitted data √√
Published/presented √√
Data Updating √ ±
Missing Studies/Data ±±
Uniform outcomes √ -
Tests for heterogeneity √√
Estimating Summary Effect Measures Binomial data √√
Time-to-event data √ ±
Exploring Heterogeneity Subgroup analyses Study Level √√
Patient Level √ -BMC Medical Research Methodology 2005, 5:14 http://www.biomedcentral.com/1471-2288/5/14
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analyses beyond those planned in the original study par-
ticularly when based on IPD.
d) Analysis checking
While access to IPD may provide an opportunity to redo
the actual analysis, there is little evidence that incorrect
analyses of randomized controlled trials are frequent or
that such reanalyses are likely to alter the conclusions of a
systematic review. Of greater concern for potential bias is
the design and conduct of the individual studies and with
rare exception there is little opportunity to address these
problems with IPD or aggregate meta-analyses. A poorly
designed or conducted trial is just as likely to bias IPD as
it is aggregate data. Divergent results in a meta-analysis
often lead investigators to draw conclusions based on sub-
groups of subjects or studies. This problem may, in fact,
represent a greater temptation in IPD meta-analyses due
to ready access to individual patient characteristics.
Oxman et al have argued that this is potentially dangerous
due to the risk of being misled by both systematic error
(bias) and random error (chance) arguing that it is far
safer to base clinical decisions on a critical summary of all
available evidence rather than on a subset of studies or
patients [13].
e) Survival data
Time-to-event or survival data seems particularly suited to
IPD meta-analyses as there is often access to the actual sur-
vival time for individual patients. Duchateau et al found
significant differences between a IPD meta-analysis of
chemotherapy for head and neck cancer and a literature-
based APD when the later analysis is based on mortality at
a specific time [14]. Time-to-event analyses or estimates of
the actual survival function are more powerful than esti-
mates based on the limited number of time points gener-
ally available with aggregate data. Parmar et al have
proposed better methods for extracting summary statistics
to perform meta-analyses of the published literature for
survival endpoints [15]. They appropriately maintain that
when reporting a randomized controlled trial with sur-
vival type data, that the most appropriate summary statis-
tics are the log hazard ratio and its variance, which are
particularly designed for comparing two survival curves by
allowing for both censoring and time to an event. If the
time to an event and censoring are ignored, the log hazard
function becomes simply the log relative risk. The hazard
ratio is a global summary of the difference between two
survival curves and represents the total reduction in the
risk of death with treatment compared to controls over the
entire period of follow-up. Parmar et al point out that the
hazard ratio is most easily interpreted when the hazards
are proportional but is still valid and useful when they are
not. These summary statistics can be used to perform a
stratified analysis to combine results from each trial in a
meta-analysis. The overall log hazard ratio is a weighted
average of the log hazard ratios of each study where the
weights are inversely proportion to the variance of the log
hazard ratio for each trial. They note that the log hazard
ratio and its variance can sometimes be estimated directly
from reported trial results. The authors go on to discuss
several indirect methods for estimating the log hazard
ratio and its variance either from summary trial results or
the published survival curves. The authors studied 209
randomized controlled trials comparing the survival of
women treated for advanced breast cancer contrasting the
estimates of the log hazard ratio directly or indirectly
taken from the manuscript with those derived from sur-
vival curves. Among the three-fourths of the studies pro-
viding some summary data, the survival curve estimate of
the log hazard ratio was nearly identical to that reported
directly in the manuscript. There was no evidence of a sys-
tematic bias although the survival curve estimate tended
to underestimate the treatment effect provided directly
from the papers. Several additional techniques have been
proposed for combining survival curves from APD. Earle
et al examined the accuracy of these techniques from stud-
ies of patients treated with chemotherapy for advanced
non-small cell lung cancer and compared each method's
summary curve with that generated by the corresponding
IPD meta-analysis [16]. The authors found that all meth-
ods were able to accurately reproduce summary survival
curves statistically similar to the IPD-derived curves with
maximum discrepancies ranging from 1.8% to 4.7%. The
optimal method was found to depend upon the character-
istics of the data and the purpose of the analysis. In addi-
tion to having a role in providing summary data when
resources or time are limited or when IPD is not available,
it has been proposed that APD meta-analyses of time-to-
event studies should be performed to determine whether
it would be worthwhile proceeding with the more
resource-dependent IPD meta-analysis [17].
f) Exploring heterogeneity
The major advantage of IPD as opposed to APD meta-
analysis is the ability to study the impact of individual
patient level characteristics. It is important to note, how-
ever, that such analyses are often not prespecified and are
therefore, by definition, secondary, exploratory or
hypothesis generating in nature. There is little debate that
the exploration of patient-level characteristics is best
undertaken with patient-level data. The use of averages or
proportions of patient characteristics in trials may lead to
the common ecological bias, often underestimating the
influence of such characteristics [18]. On the other hand,
IPD offers no inherent advantage in the exploration of
study level features such as study design characteristics. It
must be remembered, in either case, such analyses are
generally not pre-specified in either the meta-analysis or
in the individual trials, which were generally underpow-
ered to address subgroup evaluations. Such statistical lim-BMC Medical Research Methodology 2005, 5:14 http://www.biomedcentral.com/1471-2288/5/14
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itations in subgroup or meta-regression analyses are
equally applicable to IPD and APD meta-analyses.
Equivalence of meta-analysis using APD and IPD
Olkin and Sampson have shown that summary estimates
obtained from a meta-analysis of APD are essentially
equivalent to the least squares estimate of IPD computed
from a two-way fixed-effects model without interaction
where the effects in the model are those due to treatment
and due to different studies, respectively [8]. Therefore, as
long as the same set of studies are used for both, there
appears to be no difference between a meta-analysis of the
summary effect estimates obtained from each study and
that obtained by pooling the original patient data. While
Olkin and Sampson demonstrated this somewhat surpris-
ing result when the observations are independent within
and across studies based on a common variance, Mathew
and Nordstrom confirmed these findings in a much more
general setting where the observations within a study are
not necessarily independent and the observations across
studies can have different covariance matrices [19]. Sev-
eral investigators have attempted to compare the results of
APD meta-analyses often based on published results to
those of IPD. Needless to say, different investigators have
reached different conclusions from these comparisons. A
recent study by Angelillo and Villari contrasted a meta-
analysis of APD based on published studies of the perina-
tal transmission rate with Cesarean section in HIV-posi-
tive women to a previously reported IPD based meta-
analysis [20]. The two meta-analytic methods were found
to yield very similar results although no formal compari-
son was made.
Discussion
Many of the most important and valued features of sys-
tematic reviews and formal meta-analyses in general are
addressed by both IPD and APD meta-analyses. While
IPD studies may more often obtain unpublished data and
provide opportunity for data checking and updating, such
features are not inherent to IPD meta-analyses but are
largely attributable to the great resources and time
devoted to such studies. Failure to obtain data on all
patients and from all trials may lead to an acquisition bias
since the missing studies or patients may not be missing
completely at random. Clearly, IPD is advantageous when
different outcomes or cutpoints are reported in the APD.
Alternatively, when based on the same studies, summary
effect measures based on IPD and APD meta-analyses are
virtually identical. Survival data would appear to be one
area where IPD meta-analyses have a clear advantage.
However, several techniques have been developed and
validated which provide estimates of survival outcomes
with APD that are similar to those derived from IPD. APD
meta-analyses of time-to-event studies may inform inves-
tigators as to whether it would be worthwhile proceeding
with the more resource-intensive IPD meta-analysis.
While both approaches permit exploration of study and
summary patient sources of heterogeneity, only IPD per-
mits full exploration of and adjustment for patient charac-
teristics. It is important to remember, that such analyses
are only exploratory and hypothesis generating. It is
important to avoid the temptation to analyze IPD without
consideration of the separate data sources and the second-
ary nature of such analyses. IPD offers advantages and,
when feasible, should be considered the best opportunity
for summarizing the results of multiple studies. However,
the resources, time and cooperation required for such
studies will continue to limit their use in many important
areas of clinical medicine which can be meaningfully and
cost-effectively approached by properly performed APD
meta-analyses.
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